Barclays set a €100.00 ($119.05) price objective on Bayer (FRA:BAYN) in a report issued on Wednesday. The brokerage currently has a sell rating on the healthcare company’s stock.

A number of other equities research analysts have also weighed in on the stock. Berenberg Bank set a €124.00 ($147.62) price objective on shares of Bayer and gave the company a neutral rating in a report on Tuesday. J P Morgan Chase & Co set a €125.00 ($148.81) price objective on shares of Bayer and gave the company a buy rating in a report on Friday, December 1st. Sanford C. Bernstein set a €131.00 ($155.95) price objective on shares of Bayer and gave the company a buy rating in a report on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) price objective on shares of Bayer and gave the company a neutral rating in a report on Tuesday, November 28th. Finally, UBS set a €125.00 ($148.81) price objective on shares of Bayer and gave the company a buy rating in a report on Monday, November 27th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of €122.19 ($145.46).

Bayer (BAYN) traded down €0.90 ($1.07) during trading on Wednesday, reaching €103.95 ($123.75). 861,469 shares of the company’s stock traded hands. Bayer has a 1-year low of €86.60 ($103.10) and a 1-year high of €123.82 ($147.40).

COPYRIGHT VIOLATION WARNING: “Bayer (BAYN) Given a €100.00 Price Target by Barclays Analysts” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://theolympiareport.com/2017/12/07/bayer-bayn-given-a-100-00-price-target-by-barclays-analysts.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.